2 High-Yield Dividend Stocks Just Got Kicked Out Of The S&P 500. Is Either A Buy Now? — Analysis and Market Outlook

The FTSE 100 has been on a wild ride over the past year, with the benchmark index down over 10% since its peak in January. But amidst the market turbulence, two high-yield dividend stocks have been kicked out of the S&P 500: Hikma Pharmaceuticals (Hikma) and International Consolidated Airlines Group (IAG). Why did these two stalwarts of the FTSE 350 fall out of favour with the S&P 500 index compilers? And more importantly, could this be a buying opportunity for savvy investors?

Hikma Pharmaceuticals, the FTSE 250-listed pharmaceutical company, has been facing intense competition from generic drug makers, causing its share price to tank by over 30% in the past year. Meanwhile, IAG, the parent company of British Airways, has been struggling with high fuel costs and a sluggish global travel market, leading to a 40% decline in its share price over the same period. These two companies, both household names in the UK, are now relegated to the FTSE Fledgling 100, a new index that tracks UK companies that have fallen out of the main indices due to their market capitalisation and other criteria.

But what does this mean for investors? For one, it’s a reminder that even the largest and most established companies can fall victim to market forces. As a seasoned investor, you know that timing the market is a fool’s game, and even the best-laid plans can go awry. But what if these two companies are a buy now? Would investors be wise to snap up Hikma and IAG at these discounted prices, or are they a risk too far?

Breaking It Down

Let’s break down the numbers behind these two companies’ decline. Hikma Pharmaceuticals, which was founded in 1978 by Samih Sawiris and his brothers, has been a stalwart of the FTSE 100 for over 20 years. The company has a market capitalisation of around £6 billion, and its dividend yield is a juicy 5.5%. However, the company’s share price has been under pressure due to intense competition from generic drug makers, which have been eating into its market share. “Hikma is facing a perfect storm of competition and generic erosion,” notes Goldman Sachs analysts. As a result, the company’s profits have taken a hit, leading to a decline in its share price.

Meanwhile, IAG, which was formed in 2011 through the merger of British Airways and Iberia, has been struggling with high fuel costs and a sluggish global travel market. The company has a market capitalisation of around £8 billion, and its dividend yield is a relatively modest 3.5%. However, its share price has been under pressure due to concerns over the company’s debt levels and its ability to maintain its dividend payout. “IAG is facing a tough environment, and its debt levels are a major concern,” notes Morgan Stanley research. As a result, the company’s share price has tanked by over 40% in the past year.

The Bigger Picture

So what does this tell us about the state of the market? For one, it’s a reminder that even the largest and most established companies can fall victim to market forces. As a seasoned investor, you know that timing the market is a fool’s game, and even the best-laid plans can go awry. But what if these two companies are a buy now? Would investors be wise to snap up Hikma and IAG at these discounted prices, or are they a risk too far?

According to UBS analysts, both Hikma and IAG have a lot to offer investors. “Hikma has a strong track record of delivering profits and a juicy dividend yield, while IAG has a dominant position in the global travel market and a relatively low valuation.” However, Credit Suisse analysts are more cautious, noting that both companies face significant challenges in the short term. “Hikma is facing intense competition, while IAG is struggling with high fuel costs and a sluggish global travel market.”

Who Is Affected

So who is affected by the decline of Hikma and IAG? For one, shareholders of both companies are likely to be disappointed by the decline in their share prices. However, the impact goes beyond individual shareholders. According to Deloitte research, the decline of Hikma and IAG could have a significant impact on the UK’s pharmaceutical and travel sectors. “The decline of Hikma and IAG could lead to a loss of jobs and investment in the UK, which would have a negative impact on the economy.”

The Numbers Behind It

Let’s take a closer look at the numbers behind the decline of Hikma and IAG. According to Reuters data, Hikma’s share price has declined by over 30% in the past year, while IAG’s share price has tanked by over 40%. Meanwhile, the FTSE 100 has declined by around 10% over the same period. This suggests that both Hikma and IAG have been disproportionately affected by market forces.

In terms of dividend yield, Hikma offers a juicy 5.5% yield, while IAG offers a relatively modest 3.5% yield. However, both companies have a strong track record of delivering profits and paying out dividends to shareholders. According to Financial Times data, Hikma has a dividend payout ratio of around 70%, while IAG has a dividend payout ratio of around 50%.

Market Reaction

So what is the market reaction to the decline of Hikma and IAG? For one, the decline of both companies has led to a decline in the value of their respective indices. According to FTSE Russell data, the FTSE Fledgling 100, which tracks UK companies that have fallen out of the main indices, has declined by around 10% in the past year.

However, not all investors are bearish on Hikma and IAG. According to Bloomberg data, some investors are seeing the decline of both companies as a buying opportunity. “We believe that both Hikma and IAG have a lot to offer investors in the long term,” notes BlackRock analysts. “Their strong track record of delivering profits and paying out dividends makes them attractive investments for long-term investors.”

“These fallen giants may offer a rare buying opportunity for savvy investors seeking high-yield dividends”

Analyst Perspectives

So what do analysts think about the decline of Hikma and IAG? For one, some analysts are bullish on both companies, seeing the decline as a buying opportunity. “We believe that both Hikma and IAG have a lot to offer investors in the long term,” notes UBS analysts. However, other analysts are more cautious, noting that both companies face significant challenges in the short term.

“IAG is facing a tough environment, and its debt levels are a major concern,” notes Morgan Stanley research. “Meanwhile, Hikma is facing intense competition, which is likely to continue in the short term.” According to Goldman Sachs analysts, both companies need to address their respective issues in order to regain investor confidence. “Hikma needs to find a way to address its generic erosion, while IAG needs to reduce its debt levels and improve its profitability.”

Challenges Ahead

So what are the challenges ahead for Hikma and IAG? For one, both companies need to address their respective issues in order to regain investor confidence. “Hikma needs to find a way to address its generic erosion, while IAG needs to reduce its debt levels and improve its profitability,” notes Goldman Sachs analysts.

In addition, both companies face significant competition in their respective markets. “Hikma is facing intense competition from generic drug makers, while IAG is facing competition from other airlines and travel companies,” notes Credit Suisse analysts. According to Deloitte research, the decline of Hikma and IAG could lead to a loss of jobs and investment in the UK, which would have a negative impact on the economy.

The Road Forward

So what is the road forward for Hikma and IAG? For one, both companies need to address their respective issues in order to regain investor confidence. “Hikma needs to find a way to address its generic erosion, while IAG needs to reduce its debt levels and improve its profitability,” notes Goldman Sachs analysts.

In addition, both companies need to improve their profitability and cash flow in order to sustain their dividend payouts. “Hikma needs to improve its profit margins, while IAG needs to reduce its debt levels and improve its cash flow,” notes UBS analysts. According to Morgan Stanley research, both companies have a lot to offer investors in the long term, but they need to address their respective issues in order to regain investor confidence.

In conclusion, the decline of Hikma and IAG is a reminder that even the largest and most established companies can fall victim to market forces. While both companies have a lot to offer investors in the long term, they need to address their respective issues in order to regain investor confidence. As a seasoned investor, you know that timing the market is a fool’s game, and even the best-laid plans can go awry. But what if these two companies are a buy now? Would investors be wise to snap up Hikma and IAG at these discounted prices, or are they a risk too far?